Andrews MC, Chen WS, Spencer C, et al. Molecular, immune and microbial predictors of response and toxicity to combination immune-checkpoint blockade (CICB) in melanoma (MEL) patients. SMR 2017, abstract SMR02-3.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker